Advertisement
UK markets open in 7 hours

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • CRUDE OIL

    85.37
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,399.90
    -7.90 (-0.33%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • Bitcoin GBP

    51,305.12
    +275.96 (+0.54%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,865.25
    -19.77 (-0.12%)
     

  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Moving Average Crossover Alert: Catasys

Zacks Equity Research
·2-min read

Catasys, Inc. CATS could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for CATS broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

This has already started to take place, as the stock has moved lower by 47.4% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for CATS stock.

If that wasn’t enough, CATS isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.

Consider that in the last 30 days, 1 estimate has been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.

ADVERTISEMENT

That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So, either avoid this stock or consider jumping ship until the estimates and technical factors turn around for CATS. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Catasys Inc. (CATS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research